Abstract: Provided are the following: an MWW type zeolite which has many Brønsted acid sites when in the form of a proton type and which is highly suitable as a cracking catalyst for cumene; a method for producing same; and an application of same. The present invention provides an MWW type zeolite in which the ratio (B/A) of the peak intensity (B) attributable to tetracoordinate aluminum relative to the peak intensity (A) attributable to hexacoordinate aluminum is 2 or more in 27Al MAS NMR, when measured as an ammonium type. The present invention also provides a method for producing an MWW type zeolite, the method having a step for carrying out a hydrothermal synthesis reaction in the presence of: a seed crystal of an MWW type zeolite containing no organic structure-directing agent; and a reaction mixture containing a silica source, an alumina source, an alkali source, an organic structure-directing agent, and water. The reaction mixture satisfies the following molar ratio: X/SiO2<0.

Abstract: A conductive bridge memory device includes a memory cell including a first metal layer; a second metal layer; a first insulator layer having a first surface facing the first metal layer and a second surface facing the second metal layer and being a surface opposite to the first surface, and having a through hole penetrating between the first surface and the second surface; and a liquid layer being formed of liquid containing a liquid electrolyte impregnated in the through hole.

Abstract: It is provided a technique capable of noninvasively and quantitatively evaluating the state of cultured three-dimensional cell-based structure. A method of evaluating a three-dimensional cell-based structure according to the present invention comprises: performing tomography of the cultured three-dimensional cell-based structure (step S103); generating stereoscopic data indicating the three-dimensional shape of the three-dimensional cell-based structure based on image data acquired by the tomography (step S104); and counting the number of structures isolated from each other in the three-dimensional cell-based structure based on the stereoscopic data (step S105).

Abstract: The present invention provides a therapeutic agent or a prophylactic agent of dementia containing xanthine oxidase inhibitor such as a compound represented in formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: Provided is a silyl ether-containing sulfonate salt that contains an anion represented by formula (1) and a cation. (In the formula, R1 to R4 are each independently a C1-4 alkyl group. m is an integer from 1 to 3. n is an integer from 2 to 8.

Abstract: A novel therapeutic drug for malignant tumors, cancer stem cells, or fibrosis is obtained. A therapeutic drug for malignant tumors or cancer stem cells is used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof. Alternatively, a therapeutic drug for fibrosis can be used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof.

Abstract: A high-performance CB-RAM having a low operating voltage and a high switching endurance even when alumina is used for the insulator layer; wherein, an electrolyte layer impregnated in a pore of an insulator layer is configured to include a mixed ionic liquid in which is mixed a solvate ionic liquid, and a low-viscous ionic liquid being an ionic liquid having a viscosity coefficient smaller than that of the solvate ionic liquid.

Abstract: The purpose of the present invention is to provide a metal-substituted beta zeolite that exhibits a more excellent catalytic performance than conventional one, and a method for producing the same. The present invention provides a metal-substituted beta zeolite by subjecting an alkali metal-form beta zeolite produced without using an organic structure-directing agent to ion exchange with ammonium ion and then, using a filter cake procedure, to ion exchange with copper ion or iron(II) ion. The present invention also provides a metal-substituted beta zeolite which has been ion exchanged with copper ion or iron(II) ion and in which the amount of Lewis acid sites is greater than the amount of Bronsted acid sites when the amount of Bronsted acid sites and the amount of Lewis acid sites are measured by ammonia infrared-mass spectroscopy temperature-programmed desorption on the as-produced state.

Abstract: The present invention provides a therapeutic agent or a prophylactic agent of dementia containing xanthine oxidase inhibitor such as a compound represented in formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Provided is a microswitch including a first electrode, a second electrode, and a porous coordination polymer conductor, in which the porous coordination polymer conductor is represented by the following Formula (1), and a metal forming the first electrode and a metal forming the second electrode have different oxidation-reduction potentials, [MLx]n(D)y??(1), where M represents a metal ion selected from group 2 to group 13 elements in a periodic table, L represents a ligand that has two or more functional groups capable of coordination to M in a structure of L and is crosslinkable with two M's, D represents a conductivity aid that includes no metal element, x represents 0.5 to 4 and y represents 0.0001 to 20 with respect to x as 1, n represents the number of repeating units of a constituent unit represented by [MLx], and n represents 5 or more.

Abstract: A method includes acquiring starting position information of moving bodies; acquiring destination position information of movement destinations; acquiring path information indicating paths on which the moving bodies can move; calculating, for each moving body, a minimum movement amount required for the moving body to move on a path from the starting position to each movement destination, based on the starting position information, the destination position information, and the path information; allocating a movement destination not allocated to any moving body to a moving body that has a minimum movement amount being the smallest of the minimum movement amounts and that has no allocation of any movement destination; further allocating, when there is a movement destination not allocated to the moving body on a movement route, the not-allocated movement destination to the allocated moving body; and determining movement routes of the moving bodies based on the allocation.

Abstract: This application provides a method for preparing human cell-derived microcells from human cells comprising DNA of interest, comprising: a step of culturing human cells in a medium containing at least one micronucleus inducer selected from the group consisting of microtubule polymerization inhibitors (excepting colcemid), microtubule depolymerization inhibitors, and spindle checkpoint inhibitors, thereby to produce human cell-derived microcells; and a step of collecting human cell-derived microcells comprising the DNA of interest, and a method for preparing human cells comprising DNA of interest by use of the method, which can be also applied to non-human animal cells.

Abstract: The present application provides: a method for producing human induced pluripotent stem (iPS) cells comprising an exogenous chromosome having a DNA of interest using the MMCT method; and a method for expressing the exogenous gene in the human iPS cells prepared by the method for producing human iPS cells, or in undifferentiated or differentiated cells derived from the human iPS cells induced to differentiate from the human iPS cells.

Abstract: A mouse artificial chromosome vector is stable in rodent cells, tissues, and/or individuals, specifically a mouse artificial chromosome vector derived from a mouse chromosome selected from mouse chromosome 10 and mouse chromosome 16. A cell or a non-human animal may include the vector. The vector may be used for producing proteins and human antibodies.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: An object of the present invention is to provide a layer for suppressing permeation of soil moisture that has a low environmental load and can be easily constructed, and a method of forming the same. The method of forming a layer for suppressing permeation of soil moisture comprises a step of spraying coagulant for a natural rubber latex over a target soil and then spraying a natural rubber latex over the target soil, and repeating the step twice or more.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: A mental illness determination device includes a face change information acquisition unit and a mental illness determination unit. The face change information acquisition unit is configured to acquire face change information indicating a time-series change in face data of a subject when emotional stimulation information for stimulating any sense or any combination of senses among an auditory sense, an olfactory sense, a gustatory sense, a tactile sense, and a somatic sensation of the subject to change emotion, and is divided into positive information for increasing comfort and negative information for decreasing comfort is provided to the subject. The mental illness determination unit is configured to determine a state of mental illness of the subject on the basis of the face change information.

Abstract: An object of the present invention is to provide an enhancer for endogenous T-cells or B-cells having a memory function and a malignant tumor recurrence inhibitor in order to continue to reject malignant tumor over a long period of time. An enhancer for T-cells or B-cells having a memory function in an administration subject, comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and an inducer for inducing a memory function in T-cells or B-cells in an administration subject, are prepared. Also, a malignant tumor recurrence inhibitor comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding CCL19, is prepared.